← All trials
NCT05504837
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2022
- Primary completion
- Mar 31, 2024
- Completion date
- Mar 31, 2024
- First posted
- Aug 17, 2022
- Last posted
- Aug 17, 2022
- Enrollment
- 20
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Krystal Biotech, Inc.Lead sponsor
- Krystal Biotech, Inc.Study director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.